Aptose Biosciences Inc. (TSE:APS – Get Rating) (NASDAQ:APTO)’s share price hit a new 52-week low during mid-day trading on Friday . The company traded as low as C$0.90 and last traded at C$0.90, with a volume of 16937 shares traded. The stock had previously closed at C$0.93.
Analysts Set New Price Targets
Separately, Jonestrading reissued a “buy” rating and issued a C$5.00 target price on shares of Aptose Biosciences in a research report on Friday, June 3rd.
Aptose Biosciences Trading Down 4.3 %
The stock has a 50-day simple moving average of C$1.03 and a two-hundred day simple moving average of C$1.25. The company has a debt-to-equity ratio of 0.72, a quick ratio of 6.70 and a current ratio of 6.89. The firm has a market cap of C$82.14 million and a PE ratio of -1.02.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- No One Told These 3 Stocks It’s a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
- Is There a Cure for What is Ailing Teladoc Stock?
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.